M. Packer, S. Anker, J. Butler, G. Filippatos, S. Pocock, P. Carson, J. Januzzi, S. Verma, H. Tsutsui, M. Brueckmann, W. Jamal, K. Kimura, J. Schnee, C. Zeller, Daniel Cotton, E. Bocchi, M. Böhm, D. Choi, V. Chopra, E. Chuquiure, N. Giannetti, S. Janssens, Jian Zhang, J. G. González Juanatey, S. Kaul, H. Brunner-la Rocca, B. Merkely, S. Nicholls, S. Perrone, I. Piña, P. Ponikowski, N. Sattar, M. Senni, M. Séronde, J. Špinar, I. Squire, S. Taddei, C. Wanner, F. Zannad
2020.8.28NEW ENGLAND JOURNAL OF MEDICINE
tlooto Summary
SGLT2 inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes, regardless of the presence or absence of diabetes.
Abstract
Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More eviden...
Citation format
PACKER, M., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. NEW ENGLAND JOURNAL OF MEDICINE, 2020.